CN115768432A - 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 - Google Patents

使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 Download PDF

Info

Publication number
CN115768432A
CN115768432A CN202180039610.0A CN202180039610A CN115768432A CN 115768432 A CN115768432 A CN 115768432A CN 202180039610 A CN202180039610 A CN 202180039610A CN 115768432 A CN115768432 A CN 115768432A
Authority
CN
China
Prior art keywords
effective amount
days
administration
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039610.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·苏托
R·博海科
郑斗瑛
李振洙
赵显龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinot Bio Co ltd
Southern Research Institute
Original Assignee
Pinot Bio Co ltd
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinot Bio Co ltd, Southern Research Institute filed Critical Pinot Bio Co ltd
Publication of CN115768432A publication Critical patent/CN115768432A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180039610.0A 2020-04-23 2021-04-22 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 Pending CN115768432A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (1)

Publication Number Publication Date
CN115768432A true CN115768432A (zh) 2023-03-07

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039610.0A Pending CN115768432A (zh) 2020-04-23 2021-04-22 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途

Country Status (8)

Country Link
US (2) US12208112B2 (enExample)
EP (1) EP4138843A4 (enExample)
JP (1) JP2023524912A (enExample)
KR (1) KR20230004768A (enExample)
CN (1) CN115768432A (enExample)
AU (1) AU2021260964A1 (enExample)
CA (1) CA3176543A1 (enExample)
WO (1) WO2021216936A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187391A (zh) * 2023-09-15 2023-12-08 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
KR20240139581A (ko) * 2023-03-14 2024-09-23 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
KR20250067704A (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
CA2338415C (en) 1998-07-23 2006-10-10 Southern Research Institute Preparation of thioarabinofuranosyl compounds and use thereof
WO2004018494A1 (ja) 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2011109383A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
SG11201610551TA (en) * 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
CN109553651B (zh) 2015-04-03 2021-08-06 四川科伦博泰生物医药股份有限公司 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
EP3527226A4 (en) * 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
EP3746452B1 (en) * 2018-02-01 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
EP3856754A1 (en) * 2018-09-25 2021-08-04 The United States of America, as represented by the Secretary, Department of Health and Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187391A (zh) * 2023-09-15 2023-12-08 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用

Also Published As

Publication number Publication date
AU2021260964A1 (en) 2022-12-01
JP2023524912A (ja) 2023-06-13
US20210330689A1 (en) 2021-10-28
CA3176543A1 (en) 2021-10-28
KR20230004768A (ko) 2023-01-06
EP4138843A1 (en) 2023-03-01
US20250082662A1 (en) 2025-03-13
EP4138843A4 (en) 2024-07-10
US12208112B2 (en) 2025-01-28
WO2021216936A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN115768432A (zh) 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
Hopper et al. Ivermectin toxicity in 17 collies
EP3148545B1 (en) Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3662909A1 (en) Gamma secretase modulators for the treatment of immune system dysfunction
WO1995031194A1 (en) Compositions for treatment of chronic inflammatory diseases
US20140274937A1 (en) Methods of treating hematologic cancers
Anderson et al. Fludarabine: a review of its use in non-Hodgkin’s lymphoma
EP1951233B1 (en) Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf)
EP1547615B1 (en) Remedy
Patel et al. Safety level of Levofloxacin following repeated oral adminstration in White Leg Horn layer birds
Petti et al. High‐dose ARA‐C (HiDAC) plus asparaginase in elderly patients with acute non‐lymphocytic leukemia: A pilot multicentric study by the Italian cooperative group GIMEMA
Kano et al. Systemic treatment of sterile panniculitis with tacolimus and prednisolone in dogs
WO1994005287A1 (en) Prevention or treatment of sepsis with dantrolene or azumolene
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
Sadariya et al. Safety of Moxifloxacin following repeated intramuscular administration in Wistar rats
Kanaeva et al. Clinical and Experimental Substantiation of The Use of Macrolide Antibiotic in Gastrointestinal and Respiratory Diseases
EP0655918A1 (en) Treatment of cancer with azt and alkylating or intercalating agents
EP0624368A2 (en) Use of a composition for stimulating the synthesis of glutathione in the manufacture of a medicament for the treatment of acquired immune deficiency syndrome
JP2021530512A (ja) 体重増加を抑制するためのロイテリサイクリンまたはラクトバチルス・ロイテリ
Phosphate et al. Pr FLUDARABINE PHOSPHATE INJECTION, USP
Southgate Sarafin®, a novel quinolone for bacterial disease in salmon
CZ20033145A3 (cs) Identifikace parazitických plísní v organismu a jejich léčení
HK40031928A (en) Gamma secretase modulators for the treatment of immune system dysfunction
Bifano et al. 884 CALCIUM-INDUCED ECHINOCYTOSIS (E) IN HUMAN RED BLOOD CELLS FROM NEONATES (N) AND ADULTS (A)
JP3860775B2 (ja) 口腔感染動物モデルの作製方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination